Maribel Rodriguez-Torres

Summary

Affiliation: University of Puerto Rico

Publications

  1. ncbi Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    J Clin Gastroenterol 40:358-66. 2006
  2. ncbi High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    Dig Dis Sci 50:634-9. 2005
  3. ncbi On the cusp of change: new therapeutic modalities for HCV
    Maribel Rodriguez-Torres
    Fundación de Investigación de Diego San Juan, Puerto Rico Avenida de Diego 359, San Juan, Puerto Rico
    Ann Hepatol 9:123-31. 2010
  4. doi Degree of viral decline early in treatment predicts sustained virological response in HCV-HIV coinfected patients treated with peginterferon alfa-2a and ribavirin
    M Rodriguez-Torres
    Fundacion de Investigacion de Diego, Santurce, Puerto Rico
    HIV Clin Trials 11:1-10. 2010
  5. pmc Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population
    M Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    J Viral Hepat 17:139-47. 2010
  6. doi Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    N Engl J Med 360:257-67. 2009
  7. doi Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks
    Maribel Rodriguez-Torres
    CCTI, Fundacion de Investigacion de Diego, Sancture, Puerto Rico
    Liver Int 29:237-41. 2009
  8. doi Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, Santurce, Puerto Rico
    J Med Virol 80:1576-80. 2008
  9. doi Latinos and chronic hepatitis C: a singular population
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, Santurce, Puerto Rico
    Clin Gastroenterol Hepatol 6:484-90. 2008
  10. ncbi Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, PR
    Ann Hepatol 7:72-7. 2008

Detail Information

Publications19

  1. ncbi Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    J Clin Gastroenterol 40:358-66. 2006
    ..Hepatitis C virus (HCV) infection is prevalent in Latinos. There is some evidence that progression to cirrhosis is more rapid...
  2. ncbi High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    Dig Dis Sci 50:634-9. 2005
    ..A combination of esomeprazole, tetracycline, and metronidazole is effective for eradication of H. pylori in patients allergic to penicillin, for both first-line treatment and failures of prior treatment...
  3. ncbi On the cusp of change: new therapeutic modalities for HCV
    Maribel Rodriguez-Torres
    Fundación de Investigación de Diego San Juan, Puerto Rico Avenida de Diego 359, San Juan, Puerto Rico
    Ann Hepatol 9:123-31. 2010
    ..Also, a new era of resistance as a barrier to therapy will require sub typing and more viral monitoring. Overall, improved outcomes will come at the expense of more adverse events and increased costs of treatment...
  4. doi Degree of viral decline early in treatment predicts sustained virological response in HCV-HIV coinfected patients treated with peginterferon alfa-2a and ribavirin
    M Rodriguez-Torres
    Fundacion de Investigacion de Diego, Santurce, Puerto Rico
    HIV Clin Trials 11:1-10. 2010
    ..In hepatitis C virus (HCV) monoinfection, the on-treatment virological response at Weeks 4 and 12 is a strong predictor of treatment outcomes...
  5. pmc Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population
    M Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    J Viral Hepat 17:139-47. 2010
    ....
  6. doi Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    N Engl J Med 360:257-67. 2009
    ..We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously...
  7. doi Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks
    Maribel Rodriguez-Torres
    CCTI, Fundacion de Investigacion de Diego, Sancture, Puerto Rico
    Liver Int 29:237-41. 2009
    ..Hepatic steatosis is common in patients infected with hepatitis C virus (HCV). The effect of steatosis on anti-HCV therapy efficacy is unclear...
  8. doi Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, Santurce, Puerto Rico
    J Med Virol 80:1576-80. 2008
    ..More research in ethnic and racial minorities is needed to further establish optimal treatment in this population...
  9. doi Latinos and chronic hepatitis C: a singular population
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, Santurce, Puerto Rico
    Clin Gastroenterol Hepatol 6:484-90. 2008
    ..In this article we present all the available evidence on epidemiology, natural history of chronic hepatitis C, and efficacy of anti-HCV therapy in Latinos infected with HCV...
  10. ncbi Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, PR
    Ann Hepatol 7:72-7. 2008
    ..Thyroid dysfunction (TD) is associated to chronic hepatitis C (HCV) and interferon (IFN) therapy. The prevalence of TD at baseline and during IFN therapy among stages of hepatic fibrosis is unknown...
  11. ncbi Double-blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    Dig Dis Sci 51:161-7. 2006
    ..Mesalamine was effective for treatment of chronic diarrhea and moderate nonspecific colitis in HIV patients...
  12. ncbi Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, San Juan, Puerto Rico
    J Clin Virol 38:32-8. 2007
    ..We examined the safety and efficacy of peginterferon alfa-2a (peg-IFNalpha-2a) plus ribavirin (RBV) in 41HCV/HIV-coinfected patients non-responsive to prior IFN treatment...
  13. ncbi Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, Ave De Diego 359 Suite 302, Santurce, 00909, Puerto Rico
    J Hepatol 46:613-9. 2007
    ..First aim of the study was to assess changes in FPR and TTC and staging after HCV therapy vs. no treatment. Secondary aim was to study changes in FPR/staging of sustained viral responders and non-responders to Peg-IFN alfa-2a and RBV...
  14. ncbi Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?
    M Rodriguez-Torres
    Fundacion de Investigacion de Diego, Santurce, Puerto Rico
    J Med Virol 79:694-700. 2007
    ..Occult HBV infection in serum was not detected in this large immunocompetent cohort. Moreover, prior exposure to HBV did not appear to have any affect on baseline liver histology...
  15. doi Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study
    Maribel Rodriguez-Torres
    Fundacion de Investigacion de Diego, Avenida De Diego 359, Santurce, PR 09909, USA
    J Hepatol 48:756-64. 2008
    ..A large population of patients from the AIDS Pegasys Ribavirin International Co-infection Trial (APRICOT) had paired liver biopsies interpreted and graded for steatosis along with lipid measurements and anthropometric data...
  16. doi Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial
    Maribel Rodriguez-Torres
    Fundación de Investigación, San Juan, Puerto Rico 00927, USA
    HIV Clin Trials 13:142-52. 2012
    ..The safety and efficacy of weight-based ribavirin (RBV) dosing regimens in patients with HIV-HCV coinfection has not been demonstrated in randomized clinical trials...
  17. doi Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial
    Maribel Rodriguez-Torres
    Fundación de Investigación, San Juan, Puerto Rico
    J Hepatol 58:663-8. 2013
    ..We assessed the safety, tolerability, antiviral activity, and pharmacokinetics of sofosbuvir plus pegylated-interferon (PegIFN)/ribavirin (RBV) in a 28-day, dose-ranging trial in treatment-naïve patients infected with genotype 1 HCV...
  18. doi Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient
    Maribel Rodriguez-Torres
    Fundación de Investigación, San Juan, Puerto Rico
    Curr Opin Infect Dis 26:50-7. 2013
    ..Understanding DDIs between HIV antiretroviral therapy (ART) and the DAAs in development is important to assure the best management of the HIV/HCV coinfected individuals...
  19. ncbi Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis
    Maribel Rodriguez-Torres
    Fundación de Investigación, San Juan, Puerto Rico
    Clin Gastroenterol Hepatol 12:1029-37.e5. 2014
    ..We performed a blinded, randomized, controlled trial of the effects of vaniprevir with peginterferon and ribavirin in patients with cirrhosis who did not respond to prior therapy with peginterferon and ribavirin...